473 filings
Page 5 of 24
8-K
1cob7ty7sgvthbpk9d6
25 Oct 21
ADMA Biologics Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
4:30pm
424B5
l5wpc2a4c pw
21 Oct 21
Prospectus supplement for primary offering
4:36pm
8-K
q0jvf2uj2ptsy 9hc27
21 Oct 21
ADMA Biologics Announces Pricing of Public Offering for $50 Million of Common Stock
4:30pm
424B5
5xsdyu
20 Oct 21
Prospectus supplement for primary offering
5:16pm
8-K
n12kvd2
20 Oct 21
ADMA Biologics Announces Proposed Public Offering of Common Stock
4:26pm
8-K
i349kr
18 Oct 21
Departure of Directors or Certain Officers
5:28pm
8-K
klveqsg w9wx
1 Oct 21
Departure of Directors or Certain Officers
5:05pm
8-K
f3jjp7r 6w7dt
3 Sep 21
Entry into a Material Definitive Agreement
5:03pm
424B5
yuddbvbg8jl71
3 Sep 21
Prospectus supplement for primary offering
5:01pm
8-K
oztst
17 Aug 21
Termination of a Material Definitive Agreement
4:46pm
8-K
8fc86r
16 Aug 21
ADMA Biologics Receives FDA Approval for ADMA BioCenters Plasma Collection Facility in Maryville, TN
5:15pm
8-K
4xwyvcq
12 Aug 21
ADMA Expands Commercial IG Product Offering with Additional BIVIGAM and NABI-HB Vial Sizes
12:00am
8-K
jgd g3nodfa9nazlml4
12 Aug 21
ADMA Biologics Reports Record Second Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments
12:00am
EFFECT
2jhfi
4 Aug 21
Notice of effectiveness
12:15am
CORRESP
8sazi9
30 Jul 21
Correspondence with SEC
12:00am
8-K
compf7v88sicryesrlu
27 Jul 21
Other Events
7:00am
8-K
kqs 9uxcqjvgy
20 Jul 21
ADMA Biologics Announces Successful Completion of FDA Pre-Approval Manufacturing Facility Inspection
4:31pm
8-K
4r2lhug irym
14 Jun 21
Departure of Directors or Certain Officers
5:00pm